Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03273153 · ClinicalTrials.gov registry record · Phase 3
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 446
- Enrollment target
NCT03273153 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 446 participants.
The verdict
NCT03273153, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 446 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.
Interventions
- DRUG Pembrolizumab
- DRUG Atezolizumab
- DRUG Cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2021-02-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03273153
The ClinicalTrials.gov registry entry for NCT03273153 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03273153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03273153 about?
NCT03273153 is a clinical study titled "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma". This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.
What is the current status of trial NCT03273153?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2017-12-11. Estimated completion is 2021-02-19.
What interventions are being tested in trial NCT03273153?
The interventions under investigation include: Pembrolizumab (DRUG), Atezolizumab (DRUG), Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT03273153?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.